Use of AEMs and SCD risk
| SCD cases n=926 | Controls n=9832 | OR* (95% CI) | OR† (95% CI) | |
|---|---|---|---|---|
| Overall use | ||||
| Never use | 879 (94.9) | 9583 (97.5) | 1.0 (reference) | 1.0 (reference) |
| Past use | 24 (2.6) | 1 66 (1.7) | 1.5 (1.0 to 2.4) | 1.4 (0.9 to 2.3) |
| Current use | 23 (2.5) | 83 (0.8) | 2.8 (1.7 to 4.6) | 2.6 (1.5 to 4.3) |
| Use for epilepsy | ||||
| Current use | 14 (1.5) | 49 (0.5) | 2.7 (1.4 to 5.3) | 2.8 (1.4 to 5.3) |
| Use for stable epilepsy | ||||
| Current use | 6 (0.7) | 37 (0.4) | 1.7 (0.7 to 4.1) | 1.6 (0.7 to 4.1) |
| Use for symptomatic epilepsy | ||||
| Current use | 8 (0.9) | 12 (0.1) | 6.5 (2.4 to 17.5) | 6.4 (2.4 to 17.4) |
| Use by non-epilepsy patients | ||||
| Current use | 9 (1.0) | 34 (0.4) | 2.7 (1.3 to 5.9) | 2.3 (1.01 to 5.2) |
Data are expressed as number (%) unless otherwise indicated.
*ORs matched for age, gender, practice, and calendar time.
†ORs matched for age, gender, practice, and calendar time, adjusted for heart failure.
AEM, antiepileptic medication; SCD, sudden cardiac death.